ACC 23: Pulsed Field Ablation in Persistent Atrial Fibrillation Patients: The PULSED AF Trial

Подробнее о видео

Principal Investigator, Dr Atul Verma (McGill University Health Centre, CA) joins us on-site at ACC's 2023 Scientific Sessions to outline the findings of the PULSED-AF Trial (Medtronic Cardiac Rhythm and Heart Failure). In this prospective, multicenter study, 421 patients with persistent atrial fibrillation (AF) were treated with the Medtronic PulseSelect Pulsed Field Ablation (PFA) System to study the safety and effectiveness of this device.

Questions:
1. What is the background of this trial?
2. What are benefits of this novel technology?
3. Can you tell us about the study design, eligibility criteria and outcome measures?
4. What are the findings presented at ACC?
5. What are the potential implications of this data on practice and further research?
6. What are the next steps?

For more content from ACC.23/WCC and the Late-breaker Discussion series head to Late-Breaking Science Video Collection.

Recorded on-site at ACC 2023, New Orleans.

Visit Radcliffe Cardiology:

This content is intended for healthcare professionals only.

Radcliffe brings medical knowledge, insight and innovation to life for CV clinicians around the world, using our communications & creative expertise, our platforms and connections across the community to help transform theory into practice faster.

Like us on Facebook:
Follow us on Twitter: